NervGen Pharma Reports Positive Results from Phase 1b/2a CONNECT Study in Chronic Spinal Cord Injury
I'm PortAI, I can summarize articles.
NervGen Pharma Corp. announced positive results from its Phase 1b/2a CONNECT Study for chronic spinal cord injury. The company will present clinical data at the Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium on February 15-17, 2026, in Washington, DC. The data shows durable improvements in function, independence, and quality of life for individuals treated with NVG-291. This announcement is for informational purposes only and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments